How Great MedTech Gets Built

What separates a great medical device from one that never makes it to market? In this episode of Med Tech Gurus, we sit down with Ian McEachern, Founder of Nerdian and a veteran engineer behind artificial hearts, implantable blood pumps, surgical robotics, and other mission-critical medical technologies. Drawing on more than two decades of experience, Ian shares what it really takes to transform ambitious ideas into products that clinicians trust and patients depend on. We explore why successful MedTech innovation starts by reducing technical risk early, building experiments before products, partnering instead of reinventing the wheel, and bringing engineers and clinicians together throughout the design process. Ian also shares practical lessons on systems engineering, design for manufacturing, team leadership, and scaling complex medical devices from prototype to commercialization. If you're interested in medical device development, MedTech innovation, surgical robotics, product development, systems engineering, design for manufacturing, healthcare entrepreneurship, or MedTech commercialization, this episode delivers a behind-the-scenes look at how world-class medical technologies are built.

For decades, stroke survivors have been told that once recovery plateaus, there's little more that can be done. What if that's no longer true? In this episode of Med Tech Gurus, Leo Petrossian, CEO of Kandu, returns to discuss the only FDA-cleared at-home brain-computer interface for stroke rehabilitation and how it's helping survivors regain hand function—even years after a stroke. By combining EEG brain-computer interface technology, neuroplasticity, robotics, and virtual clinical coaching, Kandu is challenging long-held assumptions about what's possible in neurological recovery. Leo shares why the future of stroke rehabilitation isn't just breakthrough technology—it's bringing advanced therapy into the home, pairing patients with expert coaching, and giving millions of stroke survivors something they often lose: hope. We also explore the commercialization of breakthrough neurotechnology, the challenges of reimbursement, the power of real-world clinical evidence, and why the next frontier of MedTech is creating solutions patients can successfully use every day. If you're interested in stroke rehabilitation, brain-computer interfaces, neuroplasticity, digital therapeutics, home healthcare, neuroscience, or MedTech innovation, this episode offers an inspiring look at the future of neurological recovery.

What if the secret to better healthcare technology isn't building smarter apps—but designing around human behavior? In this episode of Med Tech Gurus, we sit down with Rio Wilson, Founder of Brain-Body Therapy, to explore why the most successful digital health solutions don't ask people to create new habits—they strengthen the ones they already have. By integrating cognitive behavioral therapy, exercise science, neuroplasticity, and behavioral coaching into a single experience, Rio is redefining how technology can support mental wellness in a way that's practical, engaging, and sustainable. Rather than designing for features, she designs for people—meeting users where they are and making healthy choices easier to maintain. Along the way, Rio shares valuable lessons on behavior change, patient engagement, trust, and what it takes to build technology that people don't just download—but actually use. If you're interested in digital therapeutics, mental health innovation, behavioral science, patient engagement, digital health, healthcare entrepreneurship, or human-centered product design, this episode delivers a fresh perspective on creating technology that truly changes lives.

What if the future of MedTech isn't collecting more data—but finally connecting it? In this episode of Med Tech Gurus, we talk with Plarent Ymeri, Founder and CEO of Smarteeva, to explore how artificial intelligence is transforming post-market surveillance, quality management, and regulatory compliance by turning disconnected information into actionable intelligence. Plarent explains why many medical device companies don't have a recall problem—they have a visibility problem. When complaints, risk files, field service, engineering, and regulatory data remain trapped in separate systems, organizations miss early warning signals that could improve patient safety and product performance. By connecting these data sources with AI, manufacturers can identify risk sooner, automate regulatory workflows, and make smarter decisions across the entire product lifecycle. We also discuss AI-powered FDA Medical Device Reporting (MDR), scaling a healthcare software company, fundraising lessons, and why the best founders spend more time winning customers than chasing investors. If you're interested in MedTech AI, post-market surveillance, FDA compliance, quality management systems, regulatory affairs, healthcare software, medical device safety, or healthcare innovation, this episode delivers a compelling vision for the future of intelligent MedTech.

What if we've been thinking about healthcare delivery all wrong? In this episode of Med Tech Gurus, Ryan Polselli, MD, Founder of MammoLink, challenges one of healthcare's oldest assumptions: making care available doesn't mean patients will use it. After performing more than 55,000 mobile breast cancer screenings, Ryan discovered that convenience—not awareness—is often the biggest driver of preventive care. Ryan shares how he's bringing breast cancer screening directly to employers, communities, and underserved populations while using AI to identify women with dense breast tissue and accelerate follow-up care. Along the way, he explains why healthcare organizations must design around human behavior—not just clinical workflows. Whether discussing patient engagement, mobile healthcare, AI in radiology, or scaling a healthcare startup from the ground up, Ryan delivers a compelling message for every healthcare leader: The future of healthcare isn't about asking patients to come to us. It's about meeting them where they are. If you're interested in breast cancer screening, mobile healthcare, preventive medicine, digital health, AI in radiology, healthcare innovation, or entrepreneurship, this episode offers a fresh blueprint for increasing access by redesigning the patient experience.

What if the biggest obstacle to innovation isn't bureaucracy—it's a lack of clarity? In this episode of Med Tech Gurus, we welcome Aleksandar Ciric, General Manager of Novo Nordisk Austria, whose remarkable journey spans building American football in Serbia from the ground up to leading one of healthcare's top-performing business units. Through both experiences, he's learned a powerful lesson: speed and compliance aren't competing priorities—clarity makes both possible. Aleksandar shares practical insights on accelerating decision-making, creating role clarity, leading through change, building high-performance teams, and why great leaders model urgency before expecting it from others. He also explains why innovation doesn't begin with bigger budgets—it begins with leaders willing to communicate clearly, move decisively, and build trust. If you're interested in healthcare leadership, MedTech commercialization, organizational culture, decision-making, innovation, executive leadership, or high-performance teams, this episode offers practical lessons you can apply immediately.

What if AI isn't software anymore? In this episode of Med Tech Gurus, we sit down with Scott Schell, MD, PhD, MBA, Chief Medical Officer at Cognizant, to explore one of the most important questions in healthcare AI: Who is responsible when the model is wrong? Scott argues that as AI begins reviewing charts, drafting communications, processing claims, and influencing clinical decisions, it starts behaving less like software and more like a member of the workforce. And every member of the workforce needs a job description, supervision, accountability, and clear escalation pathways. We discuss AI governance, workflow design, shadow AI, and why the smartest health systems aren't starting with technology—they're starting with operational problems that need solving. If you're interested in AI in healthcare, digital transformation, clinical operations, healthcare leadership, or AI governance, this episode delivers practical insights on moving AI from experimentation to real-world impact.

What if the biggest risk in AI isn't the technology—it's the system behind it? In this episode of Med Tech Gurus, we sit down with Henna Karna, Co-Founder and President of NeuroVitals, to explore why artificial intelligence doesn't fix broken organizations—it accelerates whatever already exists. Drawing on leadership experience at Google, AXA, and AIG, Henna shares a powerful perspective on the intersection of AI, healthcare, and mental wellness. While many organizations view AI as a solution, she argues that success depends on understanding culture, workflows, and human behavior before technology is deployed. We also explore NeuroVitals' mission to combine AI, biomarkers, and behavioral science to help individuals better manage their mental and physical well-being. From personalized wellness journeys to bridging gaps between therapy sessions, Henna explains how AI can support—not replace—human connection and clinical judgment. If you're interested in AI in healthcare, mental health innovation, digital health, patient engagement, behavioral science, or healthcare transformation, this episode offers a fresh perspective on how to build technology that strengthens people instead of simply automating processes.

What if the biggest bottleneck in MedTech innovation isn't science—but compliance? In this episode of Med Tech Gurus, we sit down with Zahra Timsah, Founder and CEO of i-GENTIC AI, to explore how artificial intelligence is transforming FDA readiness, regulatory operations, and healthcare compliance. With experience spanning oncology research, drug discovery, engineering, and international regulatory systems, Zahra brings a rare perspective to one of healthcare's least glamorous—but most consequential—challenges: getting innovation through the regulatory bottleneck and into patients' hands faster. What makes her story especially compelling is that this mission is personal. After witnessing a life-saving diagnostic delayed by regulatory friction, Zahra began pursuing a different vision: using AI not to replace expertise, but to augment it. We dive into her concept of "governance by design," where compliance becomes proactive instead of reactive, embedded into every stage of development rather than treated as a last-minute hurdle. Zahra also explains how contextual AI agents can act like a "digital FDA reviewer," helping companies identify inconsistencies, reduce documentation friction, and prepare stronger submissions before they ever reach regulators. The conversation also explores why most operational bottlenecks are documentation-driven rather than scientific, why specialized AI matters more than general-purpose tools, and how AI-assisted services may become the next major evolution in healthcare compliance. If you're interested in AI in healthcare, FDA strategy, MedTech compliance, regulatory affairs, healthcare AI, or digital quality systems, this episode delivers a compelling look at how intelligent compliance may become a competitive advantage for the next generation of MedTech innovators.

Everyone wants to apply AI to drug development. But what if the smartest place to start isn't the technology at all—it's the bottleneck. In this episode of Med Tech Gurus, we sit down with Anastasia Christianson, former innovation and AI leader at Pfizer and Johnson & Johnson, now Managing Principal at EPAM Systems, to explore how artificial intelligence can move beyond experimentation and begin transforming clinical development. Anastasia makes a compelling case that successful AI adoption starts not with tools, but with business problems—specifically the friction points slowing trial design, patient recruitment, protocol optimization, and execution. Rather than chasing "AI everywhere," she argues companies should focus AI where it can solve high-impact challenges and deliver measurable outcomes. We dive into digital twins, virtual trials, synthetic control arms, and AI-driven patient engagement, exploring how these technologies are already improving clinical trial design and could ultimately reshape how therapies are brought to market. Anastasia also shares practical lessons on change management, scaling innovation inside complex organizations, and why process redesign—not technology alone—is often what determines whether transformation succeeds. If you're interested in AI in pharma, clinical trial innovation, digital twins, drug development, or biotech strategy, this episode offers a compelling roadmap for where the next wave of innovation is heading.